METHOD FOR PREDICTING CARDIOTOXICITY RISK IN CANCER PATIENTS RECEIVING ANTHRACYCLINES CHEMOTHERAPY

The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KLEINJANS, Jos, HEYMANS, Stephane, MONTERO ARGUDO, Jose, Anastasio, SALVADOR COLOMA, Carmen, GONZÁLEZ-KING, Hernán, SEPÚLVEDA SANCHIS, Pilar, CASTELLANO IZQUIERDO, Delia, HERNÁNDIZ MARTINEZ, Amparo, PEIRÓ MOLINA, Esteban, HERVÁS MARÍN, David, PANADERO ROMERO, Joaquín, TEJEDOR GASCÓN, Sandra, SANCHEZ SANCHEZ, Rafael, A. GARCÍA, Nahuel, SANTABALLA BELTRÁN, Ana, DORRONSORO GONZÁLEZ, Akaitz, CAIMENT, Florian, CIRIA CALDUCH, María, ONTORIA OVIEDO, Imelda, MERKEN, Jort, CARRERO GARCÍA, Rubén
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.